Analyst Price Target is $89.14
▲ +93.92% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Enanta Pharmaceuticals in the last 3 months. The average price target is $89.14, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 93.92% upside from the last price of $45.97.
Current Consensus is
The current consensus among 7 investment analysts is to buy stock in Enanta Pharmaceuticals. This rating has held steady since November 2021, when it changed from a Hold consensus rating.
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.